<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=2700&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="89771" class="table-">
                
                <td>Feb. 19, 2021, 12:31 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Number of participants with any hematological and biochemical laboratory abnormality at Day 1;Number of participants with any hematological and biochemical laboratory abnormality at Day 2;Number of participants with any hematological and biochemical laboratory abnormality at Day 31;Number of participants with any hematological and biochemical laboratory abnormality at Day 32;Number of participants with any hematological and biochemical laboratory abnormality at Day 38;Number of participants with any hematological and biochemical laboratory abnormality at Day 8;Number of participants with any hematological and biochemical laboratory abnormality at screening;Number of participants with any unsolicited adverse event (AE) during 30-day follow-up period after first vaccination (first vaccination occurs on Day 1);Number of participants with any unsolicited AE during 30-day follow-up period after second vaccination (second vaccination occurs on Day 31);Number of participants with at least 1 adverse event of special interest (AESI) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31);Number of participants with at least 1 medically attended AE (MAE) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31);Number of participants with at least 1 serious adverse event (SAE) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31);Number of participants with at least 1 solicited administration site event during 7-day follow-up period after first vaccination (first vaccination occurs on Day 1);Number of participants with at least 1 solicited administration site event during 7-day follow-up period after second vaccination (second vaccination occurs on Day 31);Number of participants with at least 1 solicited systemic event during 7-day follow-up period after first vaccination (first vaccination occurs on Day 1);Number of participants with at least 1 solicited systemic event during 7-day follow-up period after second vaccination (second vaccination occurs on Day 31)
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Number of participants with any hematological and biochemical laboratory abnormality at Day 1;Number of participants with any hematological and biochemical laboratory abnormality at Day 2;Number of participants with any hematological and biochemical laboratory abnormality at Day 31;Number of participants with any hematological and biochemical laboratory abnormality at Day 32;Number of participants with any hematological and biochemical laboratory abnormality at Day 38;Number of participants with any hematological and biochemical laboratory abnormality at Day 8;Number of participants with any hematological and biochemical laboratory abnormality at screening;Number of participants with any unsolicited adverse event (AE) during 30-day follow-up period after first vaccination (first vaccination occurs on Day 1);Number of participants with any unsolicited AE during 30-day follow-up period after second vaccination (second vaccination occurs on Day 31);Number of participants with at least 1 adverse event of special interest (AESI) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31);Number of participants with at least 1 medically attended AE (MAE) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31);Number of participants with at least 1 serious adverse event (SAE) from first administered dose up to 30 days after last dose (second vaccination occurs on Day 31);Number of participants with at least 1 solicited administration site event during 7-day follow-up period after first vaccination (first vaccination occurs on Day 1);Number of participants with at least 1 solicited administration site event during 7-day follow-up period after second vaccination (second vaccination occurs on Day 31);Number of participants with at least 1 solicited systemic event during 7-day follow-up period after first vaccination (first vaccination occurs on Day 1);Number of participants with at least 1 solicited systemic event during 7-day follow-up period after second vaccination (second vaccination occurs on Day 31)
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>